pathogen or infections with rare and unusual agents, MPS can be used to rapidly obtain sequence information that can facilitate the development of diagnostic reagents [6] [7] [8] [9] [10] [11] [12] [13] . A good example of this is the recent human beta-coronavirus in late 2012, in which genome sequence information was made available using MPS in a matter of weeks 14 and might actually be possible within days using the most recent machines. Many microorganisms in the environment are not able to be cultured. So another advantage of MPS over traditional methods is that genome information can potentially be obtained directly from the sample without prior culture.
In the not-so-distant future we can imagine the following scenario in a doctor's surgery or hospital ward. A febrile traveller presents and a throat swab is taken. The sample is placed in a hand-held diagnostic device that processes the sample through its microfluidics, extracting nucleic acids. Single molecule sequencing occurs, rapidly generating gigabases of data that are analysed by an in-built microprocessor, which compares it to a database for matches with known microorganisms. A best-match reveals a high probability of an exotic viral infection. Combined with wireless and an Internet connection, there is the possibility of instant disease notification of the infection to relevant public health authorities. For less serious infections, the same technology could be used for real-time global disease monitoring. There are obviously many important quality control and ethical issues to be solved first. However, the main challenge to the realisation of such a scenario is, surprisingly, not primarily technical.
Sadly, we might all be out of a job sooner than you think!
